Expression of somatostatin receptors in human pancreatic tumor

Chengwei Tang, Izäk Biemond, Hein W. Verspaget, G. Johan A Offerhaus, Cornelis B H W Lamers

Research output: Contribution to journalArticle

Abstract

Somatostatin (SST) and its analogues are candidates for use as endocrine agents in the treatment of pancreatic neoplasm. To determine whether the status of SST receptors in the human pancreatic tumors differs from that in the tumor-free pancreata of the human and whether pancreatic adenocarcinoma expresses the same subgroup of SST receptors as found in gastrinomas, this study visualized and characterized SST receptors in human control pancreata (n = 10) as well as pancreatic cancers (n = 12) and gastrinomas (n = 8) with storage phosphor autoradiography. Both pancreatic adenocarcinoma and gastrinoma expressed specific SST receptors. The binding capacity (B(max) 35.4 ± 7.6 fmol/mg protein) and the affinity (K(d), 0.32 ± 0.27 nM) of SST receptors in gastrinomas were significantly higher than in pancreatic cancers (B(max), 15 ± 2.5 fmol/mg protein; K(d), 2.16 ± 0.4 nM). No specific SST receptors were detected in the human control pancreata. Octreotide showed similarly high potencies of inhibition of 125I-SST-28 binding as SST-28 in gastrinomas. Unlike gastrinomas, little competitive binding of 125I-SST- 28 was found with octreotide in pancreatic cancers. In conclusion, compared with the control pancreas, an up-regulation of SST receptors was present in both pancreatic cancer and gastrinoma. The subgroup of SST receptors in pancreatic cancers differs from that in gastrinomas.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalPancreas
Volume17
Issue number1
StatePublished - Jul 1998
Externally publishedYes

Fingerprint

Gastrinoma
Somatostatin Receptors
Pancreatic Neoplasms
Somatostatin-28
Pancreas
Neoplasms
Octreotide
Adenocarcinoma
Competitive Binding
Somatostatin
Autoradiography
Up-Regulation

Keywords

  • Gastrinoma
  • Pancreatic cancer
  • Somatostatin receptor

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Tang, C., Biemond, I., Verspaget, H. W., Offerhaus, G. J. A., & Lamers, C. B. H. W. (1998). Expression of somatostatin receptors in human pancreatic tumor. Pancreas, 17(1), 80-84.

Expression of somatostatin receptors in human pancreatic tumor. / Tang, Chengwei; Biemond, Izäk; Verspaget, Hein W.; Offerhaus, G. Johan A; Lamers, Cornelis B H W.

In: Pancreas, Vol. 17, No. 1, 07.1998, p. 80-84.

Research output: Contribution to journalArticle

Tang, C, Biemond, I, Verspaget, HW, Offerhaus, GJA & Lamers, CBHW 1998, 'Expression of somatostatin receptors in human pancreatic tumor', Pancreas, vol. 17, no. 1, pp. 80-84.
Tang C, Biemond I, Verspaget HW, Offerhaus GJA, Lamers CBHW. Expression of somatostatin receptors in human pancreatic tumor. Pancreas. 1998 Jul;17(1):80-84.
Tang, Chengwei ; Biemond, Izäk ; Verspaget, Hein W. ; Offerhaus, G. Johan A ; Lamers, Cornelis B H W. / Expression of somatostatin receptors in human pancreatic tumor. In: Pancreas. 1998 ; Vol. 17, No. 1. pp. 80-84.
@article{2877ed9a768448ffb5ec9523841855b1,
title = "Expression of somatostatin receptors in human pancreatic tumor",
abstract = "Somatostatin (SST) and its analogues are candidates for use as endocrine agents in the treatment of pancreatic neoplasm. To determine whether the status of SST receptors in the human pancreatic tumors differs from that in the tumor-free pancreata of the human and whether pancreatic adenocarcinoma expresses the same subgroup of SST receptors as found in gastrinomas, this study visualized and characterized SST receptors in human control pancreata (n = 10) as well as pancreatic cancers (n = 12) and gastrinomas (n = 8) with storage phosphor autoradiography. Both pancreatic adenocarcinoma and gastrinoma expressed specific SST receptors. The binding capacity (B(max) 35.4 ± 7.6 fmol/mg protein) and the affinity (K(d), 0.32 ± 0.27 nM) of SST receptors in gastrinomas were significantly higher than in pancreatic cancers (B(max), 15 ± 2.5 fmol/mg protein; K(d), 2.16 ± 0.4 nM). No specific SST receptors were detected in the human control pancreata. Octreotide showed similarly high potencies of inhibition of 125I-SST-28 binding as SST-28 in gastrinomas. Unlike gastrinomas, little competitive binding of 125I-SST- 28 was found with octreotide in pancreatic cancers. In conclusion, compared with the control pancreas, an up-regulation of SST receptors was present in both pancreatic cancer and gastrinoma. The subgroup of SST receptors in pancreatic cancers differs from that in gastrinomas.",
keywords = "Gastrinoma, Pancreatic cancer, Somatostatin receptor",
author = "Chengwei Tang and Iz{\"a}k Biemond and Verspaget, {Hein W.} and Offerhaus, {G. Johan A} and Lamers, {Cornelis B H W}",
year = "1998",
month = "7",
language = "English (US)",
volume = "17",
pages = "80--84",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Expression of somatostatin receptors in human pancreatic tumor

AU - Tang, Chengwei

AU - Biemond, Izäk

AU - Verspaget, Hein W.

AU - Offerhaus, G. Johan A

AU - Lamers, Cornelis B H W

PY - 1998/7

Y1 - 1998/7

N2 - Somatostatin (SST) and its analogues are candidates for use as endocrine agents in the treatment of pancreatic neoplasm. To determine whether the status of SST receptors in the human pancreatic tumors differs from that in the tumor-free pancreata of the human and whether pancreatic adenocarcinoma expresses the same subgroup of SST receptors as found in gastrinomas, this study visualized and characterized SST receptors in human control pancreata (n = 10) as well as pancreatic cancers (n = 12) and gastrinomas (n = 8) with storage phosphor autoradiography. Both pancreatic adenocarcinoma and gastrinoma expressed specific SST receptors. The binding capacity (B(max) 35.4 ± 7.6 fmol/mg protein) and the affinity (K(d), 0.32 ± 0.27 nM) of SST receptors in gastrinomas were significantly higher than in pancreatic cancers (B(max), 15 ± 2.5 fmol/mg protein; K(d), 2.16 ± 0.4 nM). No specific SST receptors were detected in the human control pancreata. Octreotide showed similarly high potencies of inhibition of 125I-SST-28 binding as SST-28 in gastrinomas. Unlike gastrinomas, little competitive binding of 125I-SST- 28 was found with octreotide in pancreatic cancers. In conclusion, compared with the control pancreas, an up-regulation of SST receptors was present in both pancreatic cancer and gastrinoma. The subgroup of SST receptors in pancreatic cancers differs from that in gastrinomas.

AB - Somatostatin (SST) and its analogues are candidates for use as endocrine agents in the treatment of pancreatic neoplasm. To determine whether the status of SST receptors in the human pancreatic tumors differs from that in the tumor-free pancreata of the human and whether pancreatic adenocarcinoma expresses the same subgroup of SST receptors as found in gastrinomas, this study visualized and characterized SST receptors in human control pancreata (n = 10) as well as pancreatic cancers (n = 12) and gastrinomas (n = 8) with storage phosphor autoradiography. Both pancreatic adenocarcinoma and gastrinoma expressed specific SST receptors. The binding capacity (B(max) 35.4 ± 7.6 fmol/mg protein) and the affinity (K(d), 0.32 ± 0.27 nM) of SST receptors in gastrinomas were significantly higher than in pancreatic cancers (B(max), 15 ± 2.5 fmol/mg protein; K(d), 2.16 ± 0.4 nM). No specific SST receptors were detected in the human control pancreata. Octreotide showed similarly high potencies of inhibition of 125I-SST-28 binding as SST-28 in gastrinomas. Unlike gastrinomas, little competitive binding of 125I-SST- 28 was found with octreotide in pancreatic cancers. In conclusion, compared with the control pancreas, an up-regulation of SST receptors was present in both pancreatic cancer and gastrinoma. The subgroup of SST receptors in pancreatic cancers differs from that in gastrinomas.

KW - Gastrinoma

KW - Pancreatic cancer

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=0031866830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031866830&partnerID=8YFLogxK

M3 - Article

C2 - 9667524

AN - SCOPUS:0031866830

VL - 17

SP - 80

EP - 84

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -